{"id":32617,"date":"2025-07-01T14:43:11","date_gmt":"2025-07-01T09:13:11","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32617"},"modified":"2025-07-10T10:26:11","modified_gmt":"2025-07-10T04:56:11","slug":"pharma-news-for-sobi-gsk-ultragenyx","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx","title":{"rendered":"Sobi\u2019s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still\u2019s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schr\u00f6dinger\u2019s SGR-1505 Receives FDA Fast Track Designation for Relapsed\/Refractory Waldenstr\u00f6m Macroglobulinemia; Ultragenyx\u2019s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly\u2019s AMYVID Label Updated by FDA to Support Alzheimer\u2019s Disease Diagnosis"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e358e88826\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e358e88826\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx\/#FDA_Approves_Sobis_GAMIFANT_as_the_First_Treatment_for_Macrophage_Activation_Syndrome_in_Stills_Disease\" >FDA Approves Sobi\u2019s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still\u2019s Disease&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx\/#GSK_Slashes_Price_of_RTSS_Malaria_Vaccine_for_Children_in_Endemic_Countries_to_Under_5\" >GSK Slashes Price of RTS,S Malaria Vaccine for Children in Endemic Countries to Under $5<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx\/#Schrodinger_Receives_FDA_Fast_Track_Designation_for_SGR-1505_in_RelapsedRefractory_Waldenstrom_Macroglobulinemia\" >Schr\u00f6dinger Receives FDA Fast Track Designation for SGR-1505 in Relapsed\/Refractory Waldenstr\u00f6m Macroglobulinemia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx\/#Ultragenyx_Granted_Breakthrough_Therapy_Designation_by_FDA_for_GTX-102_in_Angelman_Syndrome\" >Ultragenyx Granted Breakthrough Therapy Designation by FDA for GTX-102 in Angelman Syndrome<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx\/#FDA_Approves_Updated_Label_for_Eli_Lillys_AMYVID_to_Aid_Alzheimers_Disease_Diagnosis\" >FDA Approves Updated Label for Eli Lilly\u2019s AMYVID to Aid Alzheimer\u2019s Disease Diagnosis<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-sobi-s-gamifant-as-the-first-treatment-for-macrophage-activation-syndrome-in-still-s-disease-nbsp\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Sobis_GAMIFANT_as_the_First_Treatment_for_Macrophage_Activation_Syndrome_in_Stills_Disease\"><\/span>FDA Approves Sobi\u2019s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still\u2019s Disease&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In a major advancement for rare inflammatory conditions, the FDA has approved <strong>GAMIFANT (emapalumab-lzsg)<\/strong> for the treatment of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophagocytic-lymphohistiocytosis-market\" class=\"ek-link\">he<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophagocytic-lymphohistiocytosis-market\" class=\"ek-link\"><strong>mophagocytic lymphohistiocytosis (HLH)\/macrophage activation syndrome (MAS)<\/strong><\/a> in patients with known or suspected <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/stills-disease-market\" class=\"ek-link\">S<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/stills-disease-market\" class=\"ek-link\"><strong>till\u2019s disease<\/strong><\/a>, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-juvenile-idiopathic-arthritis-sjia-market\" class=\"ek-link\"><strong>systemic juvenile idiopathic arthritis (sJIA)<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/adult-onset-still-disease-market\"><strong>adult-onset Still\u2019s disease<\/strong><\/a>. The approval spans both adult and pediatric populations, including newborns, who show inadequate response or intolerance to glucocorticoids or experience recurrent MAS episodes.<\/p>\n\n\n\n<p><em>&#8220;This approval brings much-needed hope to a vulnerable patient population. GAMIFANT now offers a targeted therapy for MAS in Still\u2019s disease, something we previously lacked,&#8221; said <\/em><strong><em>Dr. Alexei A. Grom<\/em><\/strong><em>, Professor of Pediatrics at Cincinnati Children\u2019s Hospital. \u201cIt allows us to better control hyperinflammation and reduce reliance on high-dose steroids.\u201d<\/em><\/p>\n\n\n\n<p>The FDA\u2019s decision was supported by pooled data from the <strong>pivotal Phase III EMERALD study (NCT05001737)<\/strong> and <strong>NI-0501-06 (NCT03311854)<\/strong>. Results showed that 54% of patients achieved complete response at Week 8, while 82% achieved clinical remission (VAS \u22641 cm). The safety profile remained consistent with prior trials, with viral infections and rash being the most common adverse events.<\/p>\n\n\n\n<p><em>\u201cWith our expertise in HLH, we understand the urgency of managing MAS quickly to improve outcomes,\u201d said <\/em><strong><em>Guido Oelkers<\/em><\/strong><em>, CEO of Sobi. \u201cGAMIFANT has already proven its value in primary HLH, and we are proud to extend its benefits to those battling MAS in Still\u2019s disease.\u201d<\/em><\/p>\n\n\n\n<p>GAMIFANT, a monoclonal antibody that blocks interferon gamma (IFN\u03b3), is now the first and only FDA-approved treatment for HLH\/MAS in Still\u2019s disease. The condition is characterized by life-threatening hyperinflammation, persistent fever, cytopenias, coagulopathies, and multi-organ complications, highlighting the urgent need for targeted treatment options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gsk-slashes-price-of-rts-s-malaria-vaccine-for-children-in-endemic-countries-to-under-5\"><span class=\"ez-toc-section\" id=\"GSK_Slashes_Price_of_RTSS_Malaria_Vaccine_for_Children_in_Endemic_Countries_to_Under_5\"><\/span>GSK Slashes Price of RTS,S Malaria Vaccine for Children in Endemic Countries to Under $5<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In a significant move toward accessible malaria prevention, <strong>Bharat Biotech<\/strong> and <strong>GSK<\/strong> have announced a dramatic price reduction for the <strong>RTS,S malaria vaccine<\/strong>, lowering its cost to <strong>below $5 per dose<\/strong> by 2028. This commitment, made as part of pledges to <strong>Gavi\u2019s 2026\u20132030 replenishment phase (Gavi 6.0)<\/strong>, is the result of expanded production, efficient manufacturing, and minimal profit margins, aimed at improving vaccine affordability and accessibility in <strong>endemic African nations<\/strong>.<\/p>\n\n\n\n<p>Dr. <strong>Krishna Ella<\/strong>, Executive Chairman of Bharat Biotech, emphasized the broader impact of this move: <em>&#8220;This pledge to Gavi 6.0 is more than a pricing announcement. It\u2019s a commitment to global equity, innovation, and collaboration. Together with GSK and our global partners, we aim to transform the malaria burden for millions of children and families.&#8221;<\/em><\/p>\n\n\n\n<p>Developed by GSK, PATH, and partners, <strong>RTS,S was the first malaria vaccine recommended by the WHO in 2021<\/strong>. Since then, GSK has invested heavily in scaling production and transferring technology to Bharat Biotech, which in turn has dedicated <strong>over $200 million<\/strong> toward new high-output facilities and development. The partnership has enabled a <strong>phased price reduction<\/strong>, with <strong>full transition of production<\/strong> to Bharat Biotech expected by 2028.<\/p>\n\n\n\n<p><em>&#8220;We partnered with Bharat Biotech in 2021 with a shared goal to get ahead of malaria,&#8221;<\/em> said <strong>Thomas Breuer<\/strong>, Chief Global Health Officer at GSK. <em>&#8220;This long-term price ambition demonstrates our joint commitment to infectious disease control and public health impact, especially for children across Africa.&#8221;<\/em><\/p>\n\n\n\n<p>With support from Gavi, the RTS,S vaccine is expected to be integrated into routine immunisation programs across 12 African countries by the end of 2025. A recent WHO evaluation of RTS,S implementation in Ghana, Kenya, and Malawi (2019\u20132023) showed a 13% reduction in all-cause mortality and a 22% drop in severe malaria hospitalizations among vaccinated children. These numbers highlight the vaccine\u2019s real-world impact in high-transmission regions.<\/p>\n\n\n\n<p>Dr. <strong>Sania Nishtar<\/strong>, CEO of Gavi, noted, <em>\u201cWe are grateful to GSK and Bharat Biotech for their innovation and commitment. This partnership enables us to protect millions more children across Africa\u2014bringing our 2030 goal of reaching 50 million children within reach.\u201d<\/em><\/p>\n\n\n\n<p>Further research is already underway at GSK to develop <strong>next-generation malaria vaccines<\/strong>, targeting different stages of the parasite\u2019s lifecycle, to expand the malaria prevention toolkit and advance global eradication efforts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-schrodinger-receives-fda-fast-track-designation-for-sgr-1505-in-relapsed-refractory-waldenstrom-macroglobulinemia\"><span class=\"ez-toc-section\" id=\"Schrodinger_Receives_FDA_Fast_Track_Designation_for_SGR-1505_in_RelapsedRefractory_Waldenstrom_Macroglobulinemia\"><\/span>Schr\u00f6dinger Receives FDA Fast Track Designation for SGR-1505 in Relapsed\/Refractory Waldenstr\u00f6m Macroglobulinemia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Schr\u00f6dinger, Inc.<\/strong> has announced that its investigational drug <strong>SGR-1505<\/strong>, a clinical-stage MALT1 inhibitor, has been granted <strong>Fast Track designation<\/strong> by the FDA for the treatment of <strong>adult patients with <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/waldenstrom-macroglobulinemia-market\" class=\"ek-link\"><strong>relapsed\/refractory Waldenstr\u00f6m macroglobulinemia<\/strong><\/a> who have previously failed at least two lines of therapy, including a <strong>BTK inhibitor<\/strong>.<\/p>\n\n\n\n<p><em>&#8220;We are excited to receive Fast Track designation for SGR-1505, which underscores the significant need in patients with Waldenstr\u00f6m macroglobulinemia,&#8221;<\/em> said <strong>Dr. Karen Akinsanya<\/strong>, President and Head of Therapeutics R&amp;D at Schr\u00f6dinger. <em>&#8220;BTK resistance remains a growing challenge, and SGR-1505\u2019s novel MALT1 mechanism offers potential as both monotherapy and part of combination regimens.&#8221;<\/em><\/p>\n\n\n\n<p>The Fast Track status is designed to accelerate the development and review process for drugs addressing serious medical conditions and unmet needs, potentially offering benefits such as more frequent interactions with the FDA, rolling submissions, and eligibility for Priority Review and Accelerated Approval.<\/p>\n\n\n\n<p>SGR-1505 is currently under evaluation in a Phase I clinical trial for relapsed\/refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). Initial results, recently presented at major hematology congresses, demonstrated a favorable safety profile and preliminary signs of efficacy, including in BTK-pretreated Waldenstr\u00f6m patients.<\/p>\n\n\n\n<p><em>&#8220;The Fast Track designation, along with our Phase I data across several B-cell malignancies, highlights SGR-1505\u2019s potential as a meaningful therapeutic option,&#8221;<\/em> said <strong>Dr. Margaret Dugan<\/strong>, Chief Medical Officer at Schr\u00f6dinger. <em>&#8220;We look forward to engaging with the FDA later this year to discuss the next phase of development.&#8221;<\/em><\/p>\n\n\n\n<p>SGR-1505 was also granted <strong>Orphan Drug Designation<\/strong> by the FDA in August 2023 for <strong>Mantle Cell Lymphoma (MCL)<\/strong>, further supporting its development in B-cell cancers with high unmet need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ultragenyx-granted-breakthrough-therapy-designation-by-fda-for-gtx-102-in-angelman-syndrome\"><span class=\"ez-toc-section\" id=\"Ultragenyx_Granted_Breakthrough_Therapy_Designation_by_FDA_for_GTX-102_in_Angelman_Syndrome\"><\/span>Ultragenyx Granted Breakthrough Therapy Designation by FDA for GTX-102 in Angelman Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Ultragenyx Pharmaceutical Inc.<\/strong> announced that the <strong>FDA<\/strong> has granted <strong>Breakthrough Therapy Designation<\/strong> to <strong>GTX-102 (apazunersen)<\/strong> for the treatment of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/angelman-syndrome-market-forecast\" class=\"ek-link\">A<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/angelman-syndrome-market-forecast\" class=\"ek-link\"><strong>ngelman syndrome<\/strong><\/a>, a rare neurogenetic disorder with no approved therapies to date.<\/p>\n\n\n\n<p><em>&#8220;FDA Breakthrough Therapy Designation underscores both the urgent need for an effective treatment for patients and families affected by Angelman syndrome and the clinically meaningful results demonstrated to date with GTX-102,&#8221;<\/em> said <strong>Eric Crombez, M.D.<\/strong>, Chief Medical Officer at Ultragenyx. <em>&#8220;With strong support from the Angelman community, our Phase III Aspire study is enrolling rapidly, and we\u2019re committed to moving GTX-102 through development as quickly as possible.&#8221;<\/em><\/p>\n\n\n\n<p>The designation is based on promising clinical data from a Phase I\/II study involving 74 pediatric patients (aged 4\u201317) with a full maternal UBE3A gene deletion, showing rapid, sustained, and ongoing improvements across multiple developmental domains after up to three years of treatment. These early results suggest substantial benefit over existing therapeutic options and support the drug\u2019s potential as a disease-modifying therapy.<\/p>\n\n\n\n<p>The Phase III Aspire study (NCT06617429) began enrollment in December 2024 and is expected to recruit approximately 120 children with genetically confirmed Angelman syndrome. In addition, Ultragenyx plans to launch the Aurora study in the second half of 2025 to explore GTX-102 in other genotypes and age groups, expanding the therapy&#8217;s potential reach.<\/p>\n\n\n\n<p>GTX-102 continues to generate strong interest within the rare disease community, and its Breakthrough Therapy Designation marks a significant regulatory milestone in addressing a long-standing unmet need in Angelman syndrome.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-updated-label-for-eli-lilly-s-amyvid-to-aid-alzheimer-s-disease-diagnosis\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Updated_Label_for_Eli_Lillys_AMYVID_to_Aid_Alzheimers_Disease_Diagnosis\"><\/span>FDA Approves Updated Label for Eli Lilly\u2019s AMYVID to Aid Alzheimer\u2019s Disease Diagnosis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Eli Lilly and Company<\/strong> announced that the <strong>FDA<\/strong> has approved a <strong>label update for AMYVID (florbetapir F 18 injection)<\/strong>, a diagnostic imaging agent used to estimate <strong>amyloid plaque density<\/strong> in the brains of patients being evaluated for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\" class=\"ek-link\">Alzheimer\u2019s disease<\/a><\/strong> and related cognitive disorders.<\/p>\n\n\n\n<p>The updated label expands AMYVID\u2019s use to aid in selecting patients for amyloid-targeting therapies, offering more flexibility in diagnosing and managing Alzheimer&#8217;s-related conditions. It also allows quantitative assessment of amyloid plaque levels, in addition to traditional visual interpretation. The revised label also reflects AMYVID\u2019s role in evaluating treatment response in clinical trials of amyloid-targeting drugs.<\/p>\n\n\n\n<p><em>&#8220;The modernization of AMYVID\u2019s label is a significant step in advancing Alzheimer\u2019s care,&#8221;<\/em> said <strong>Mark Mintun, M.D.<\/strong>, Group Vice President, Neuroscience R&amp;D at Lilly. <em>&#8220;It enables physicians to better support patients by helping them make more informed decisions, especially those being considered for amyloid-targeting therapies.&#8221;<\/em><\/p>\n\n\n\n<p>AMYVID binds to amyloid plaques, abnormal protein clumps associated with Alzheimer\u2019s, and makes them visible via<strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/positron-emission-tomography-market\" class=\"ek-link\">pos<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/positron-emission-tomography-market\" class=\"ek-link\"><strong>itron emission tomography (PET) imaging<\/strong><\/a>. A positive scan indicates a higher likelihood of Alzheimer\u2019s disease, while a negative scan suggests minimal amyloid buildup, making Alzheimer\u2019s less likely.<\/p>\n\n\n\n<p>The update comes at a time when early and accurate diagnosis of Alzheimer\u2019s is becoming increasingly critical. According to Lilly, nearly 80% of Americans prefer knowing their Alzheimer\u2019s status before significant cognitive decline, reinforcing the need for advanced diagnostics such as amyloid PET scans and blood biomarker testing.<\/p>\n\n\n\n<p>AMYVID is widely reimbursed under Medicare and private insurance plans, although coverage may vary. The updated label aims to improve diagnostic accuracy, guide therapy decisions, and ultimately enhance patient outcomes in the evolving Alzheimer\u2019s treatment landscape.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves Sobi\u2019s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still\u2019s Disease&nbsp; In a major advancement for rare inflammatory conditions, the FDA has approved GAMIFANT (emapalumab-lzsg) for the treatment of hemophagocytic lymphohistiocytosis (HLH)\/macrophage activation syndrome (MAS) in patients with known or suspected Still\u2019s disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":32618,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17030,17031,1407,7145,6641,2387,17928,17927,7483,204,704,2216,18755,349,370,420,639,22372,551,20285,4864],"industry":[17225],"therapeutic_areas":[17238,17227,17231,17241,17245,17228],"class_list":["post-32617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adult-onset-stills-disease","tag-adult-onset-stills-disease-market","tag-alzheimer","tag-alzheimers-disease-market","tag-alzheimers-disease-therapies","tag-angelman-syndrome","tag-angelman-syndrome-current-treatment-landscape","tag-angelman-syndrome-emerging-drugs","tag-angelman-syndrome-market","tag-delveinsight","tag-fda","tag-hemophagocytic-lymphohistiocytosis","tag-hemophagocytic-lymphohistiocytosis-treatment-market","tag-latest-pharma-news","tag-malaria","tag-news","tag-pharma-news","tag-positron-emission-tomography","tag-systemic-juvenile-idiopathic-arthritis","tag-waldenstrom-macroglobulinemia","tag-waldenstroms-macroglobulinemia","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-musculoskeletal","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Sobi, GSK, Ultragenyx<\/title>\n<meta name=\"description\" content=\"Sobi\u2019s GAMIFANT; GSK\u2019s RTS,S; Schr\u00f6dinger\u2019s SGR-1505; Ultragenyx\u2019s GTX-102; Lilly\u2019s AMYVID Approves Updated Label\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Sobi, GSK, Ultragenyx\" \/>\n<meta property=\"og:description\" content=\"Sobi\u2019s GAMIFANT; GSK\u2019s RTS,S; Schr\u00f6dinger\u2019s SGR-1505; Ultragenyx\u2019s GTX-102; Lilly\u2019s AMYVID Approves Updated Label\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-01T09:13:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-10T04:56:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01144244\/01-7-2025-feature.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Sobi, GSK, Ultragenyx","description":"Sobi\u2019s GAMIFANT; GSK\u2019s RTS,S; Schr\u00f6dinger\u2019s SGR-1505; Ultragenyx\u2019s GTX-102; Lilly\u2019s AMYVID Approves Updated Label","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Sobi, GSK, Ultragenyx","og_description":"Sobi\u2019s GAMIFANT; GSK\u2019s RTS,S; Schr\u00f6dinger\u2019s SGR-1505; Ultragenyx\u2019s GTX-102; Lilly\u2019s AMYVID Approves Updated Label","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-07-01T09:13:11+00:00","article_modified_time":"2025-07-10T04:56:11+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01144244\/01-7-2025-feature.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx","name":"Pharma News | Sobi, GSK, Ultragenyx","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01144244\/01-7-2025-feature.png","datePublished":"2025-07-01T09:13:11+00:00","dateModified":"2025-07-10T04:56:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Sobi\u2019s GAMIFANT; GSK\u2019s RTS,S; Schr\u00f6dinger\u2019s SGR-1505; Ultragenyx\u2019s GTX-102; Lilly\u2019s AMYVID Approves Updated Label","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sobi-gsk-ultragenyx#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01144244\/01-7-2025-feature.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01144244\/01-7-2025-feature.png","width":772,"height":482,"caption":"pharma-news-for-sobi-gsk-ultragenyx"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01144244\/01-7-2025-feature-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adult-onset Still\u2019s Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adult-onset Still\u2019s Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s disease therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman Syndrome Current Treatment Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman Syndrome Emerging Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Angelman syndrome market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hemophagocytic lymphohistiocytosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hemophagocytic Lymphohistiocytosis Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">malaria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">positron emission tomography<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Systemic Juvenile Idiopathic Arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Waldenstr\u00f6m macroglobulinemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Waldenstr\u00f6m\u2019s macroglobulinemia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adult-onset Still\u2019s Disease<\/span>","<span class=\"advgb-post-tax-term\">Adult-onset Still\u2019s Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s disease therapies<\/span>","<span class=\"advgb-post-tax-term\">Angelman syndrome<\/span>","<span class=\"advgb-post-tax-term\">Angelman Syndrome Current Treatment Landscape<\/span>","<span class=\"advgb-post-tax-term\">Angelman Syndrome Emerging Drugs<\/span>","<span class=\"advgb-post-tax-term\">Angelman syndrome market<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">hemophagocytic lymphohistiocytosis<\/span>","<span class=\"advgb-post-tax-term\">Hemophagocytic Lymphohistiocytosis Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">malaria<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">positron emission tomography<\/span>","<span class=\"advgb-post-tax-term\">Systemic Juvenile Idiopathic Arthritis<\/span>","<span class=\"advgb-post-tax-term\">Waldenstr\u00f6m macroglobulinemia<\/span>","<span class=\"advgb-post-tax-term\">Waldenstr\u00f6m\u2019s macroglobulinemia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Jul 1, 2025","modified":"Updated on Jul 10, 2025"},"absolute_dates_time":{"created":"Posted on Jul 1, 2025 2:43 pm","modified":"Updated on Jul 10, 2025 10:26 am"},"featured_img_caption":"pharma-news-for-sobi-gsk-ultragenyx\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32617"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32617\/revisions"}],"predecessor-version":[{"id":32743,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32617\/revisions\/32743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32618"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32617"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32617"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}